Price
No data yet.
Social Signal Score
Analyst Ratings
21 analystsRevenue
$341.25M+1433.17%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Pete Anevski
- Sector
- Healthcare
- Industry
- Medical - Healthcare Plans
- Employees
- 846
- Beta
- 0.97
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 9.64
Financials
Revenue
$341.25M+1433.2%Net Income
$26.25MEBITDA
$38.57MFree Cash Flow
$47.24MEPS (diluted)
$0.32Shares Outstanding (diluted)
81.17M+1326.6%Operating Expenses
$48.56MCash & Debt
$195.59MReturn of Capital
$82.78MRevenue by Segment (annual)
$1.29BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.29B | $58.52M | $0.68 |
| 2024 | $1.17B | $54.34M | $0.59 |
| 2023 | $1.09B | $62.04M | $0.65 |
| 2022 | $786.91M | $30.36M | $0.33 |
| 2021 | $500.62M | $65.77M | $0.74 |
| 2020 | $344.86M | $46.46M | $0.54 |
| 2019 | $229.68M | $-8.57M | $-0.10 |
| 2018 | $105.40M | $661.0K | $0.01 |
| 2017 | $48.58M | $-12.45M | $-2.19 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.01
- Implied price
- $38.34
- Return from $35.71
- 1.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $19.06 — -46.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 26 | 32 | 38 | 44 | 50 |
|---|---|---|---|---|---|
| -2.0% | -14.7% | -11.1% | -8.0% | -5.2% | -2.8% |
| 3.0% | -10.3% | -6.5% | -3.3% | -0.4% | 2.2% |
| 8.0% | -6.0% | -2.0% | 1.4% | 4.4% | 7.2% |
| 13.0% | -1.6% | 2.5% | 6.1% | 9.3% | 12.1% |
| 18.0% | 2.7% | 7.1% | 10.8% | 14.1% | 17.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
75+50.00%Social Signal Score
Mentions (18)
- Newszacks.com·3d ago·Positive
Progyny (PGNY) Upgraded to Strong Buy: What Does It Mean for the Stock? Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
View source ↗ - Newszacks.com·5d ago·Positive
Progyny, Inc. (PGNY) Hits Fresh High: Is There Still Room to Run? Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
View source ↗ - Newszacks.com·6d ago·Neutral
Progyny (PGNY) Is Up 3.85% in One Week: What You Should Know Does Progyny (PGNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newsmarketbeat.com·17d ago·Negative
Progyny Q3 Earnings Call Highlights Progyny NASDAQ: PGNY raised the midpoint of its full-year 2026 guidance after reporting record third-quarter revenue and profitability and securing a record 1.3 million new covered lives during its latest selling season.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Progyny, Inc. (PGNY) Q3 2026 Earnings Call Transcript Progyny, Inc. (PGNY) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·18d ago·Positive
Progyny (PGNY) Tops Q3 Earnings and Revenue Estimates Progyny (PGNY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.45 per share a year ago.
View source ↗ - Newsglobenewswire.com·27d ago·Positive
New Progyny Study Finds Significant Improvement in Menopause Symptoms Through Connected Care Model NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced findings from a new clinical outcomes study showing significant improvements in menopause symptoms among members receiving care through its Menopause and Midlife program. The research found that more than 70% of members in the study experienced i…
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
Progyny, Inc. Announces Details for Its Third Quarter 2026 Results Report NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended September 30, 2026, after the close of the market on Wednesday, November 4, 2026.
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
Progyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, announced today that it will present new research evaluating real-world outcomes from its Menopause and Midlife program and exhibit at The Menopause Society 2026 Annual Meeting in San Diego, October 20 – 24, 2026.
View source ↗ - Newszacks.com·45d ago·Neutral
Progyny (PGNY) Soars 6.3%: Is Further Upside Left in the Stock? Progyny (PGNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
View source ↗ - Newszacks.com·46d ago·Positive
PGNY or CRL: Which Is the Better Value Stock Right Now? Investors interested in Medical Services stocks are likely familiar with Progyny (PGNY) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗ - Newsglobenewswire.com·46d ago·Negative
…t Inflation Trend While Maintaining or Expanding Coverage of Services Impactful to their Workforce NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today revealed key insights from the Company's current annual selling season, based on both commitments received to date and anticipated remaining decisions which are expected to contribute 1.2 million new covered lives from launches…
View source ↗ - Newszacks.com·65d ago·Neutral
PGNY vs. CRL: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical Services sector might want to consider either Progyny (PGNY) or Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?
View source ↗ - Newsseekingalpha.com·66d ago·Positive
Progyny: Best-In-Class And Likely To Exceed Analyst Estimates In 2027 Progyny (PGNY) remains the US market leader in fertility benefits management, demonstrating robust growth, improving margins, and a compelling valuation despite recent volatility. PGNY's Q2 2026 results highlight 11% revenue growth ex-Amazon, margin expansion, and nearly 100% EPS growth guidance for 2026, supporting a continued buy rating. Secular tailwinds—rising infertility rates, delayed family formation, and underpenetrate…
View source ↗ - Newszacks.com·74d ago·Neutral
Wall Street Analysts Predict a 25.23% Upside in Progyny (PGNY): Here's What You Should Know The mean of analysts' price targets for Progyny (PGNY) points to a 25.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗ - Newsglobenewswire.com·80d ago·Neutral
Progyny, Inc. to Present at the Wells Fargo Healthcare Conference NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its Chief Financial Officer Mark Livingston will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Tuesday, September 8, 2026, at 11:00 a.m. ET.
View source ↗ - Newsmarketbeat.com·98d ago·Neutral
Progyny Sees Utilization Rebound as Early Renewals De-Risk Outlook Progyny NASDAQ: PGNY CEO Pete Anevski said the company expects member engagement and utilization to rebound following a more pronounced summer seasonal slowdown, while early renewal and new-client commitments have increased management's confidence in its outlook for the remainder of the year.
View source ↗ - Newsgurufocus.com·103d ago·Positive
Progyny Inc (PGNY) Stock Down 4.6% -- Now Undervalued? GF Score: 93/100 On August 11, 2026, Progyny Inc (PGNY) shares fell by 4.6%, bringing the current price to $26.55. The stock has seen significant volatility, with a 52-week high
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $0.37 per share
Typical surprise +7.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$0.52 vs $0.31beat
- Thu, Aug 6$0.36 vs $0.33beat
- Thu, May 7$0.30 vs $0.26beat
- Thu, Feb 26$0.15 vs $0.15beat
- Thu, Nov 6$0.16 vs $0.39miss
- Thu, Aug 7$0.20 vs $0.17beat
Estimates and results for PGNY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PGNY officers and directors.
- Bought
- —
- Sold
- $23.6m
0 trades
29 trades
- Clapp Geoffreysold
- Anevski Petersold
- Anevski Petersold
- Anevski Petersold
- Anevski Petersold
- Schlanger David Jsold
- Anevski Petersold
- Anevski Petersold
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Josh Gottheimerhouse · NJ05 · disclosed Jan 14, 2025 (39d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Aug 19, 2020 (20d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jul 17, 2020 (17d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jun 16, 2020 (26d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jun 16, 2020 (15d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
